Exkivity (mobocertinib) / Takeda  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Exkivity (mobocertinib) / Takeda
NCT04535557: An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Approved for marketing
N/A
NA
Mobocertinib 160 mg
Millennium Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
 
 
MEANING-20, NCT05863819: A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

Withdrawn
N/A
120
RoW
No Intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
12/26
02/27

Download Options